TA Associates is reviving plans to sell French cosmetic treatment company Laboratoires Vivacy, people familiar with the matter said.
The buyout firm is working with BNP Paribas SA and Rothschild & Co. on a potential divestment that could value Vivacy at about 1 billion euros ($1 billion), the people said. It has drawn interest from Asian competitors and other private equity firms, according to the people, who asked not to be identified discussing confidential information.
Founded in 2007, Vivacy specializes in manufacturing injectable hyaluronic-acid dermal filler products, which are available in more than 75 countries, according to its website. TA Associates bought a majority stake in the company in 2019 for an undisclosed sum.
Read more: BNN Bloomberg
Can't stop reading? This and all news articles are property of their creators, many are not owned or provided by Private Equity Insider. As an event organizer and community platform, we curate content from reliable sources for your suggested reading, and advise you to read the full articles from the referenced authors and sources.